Reaching a goal weight is a strange milestone. Months of tracking have all pointed at a number, the number arrives, and then the obvious question turns out to have no obvious answer: now what?
Most of the writing about GLP-1s is organized around getting somewhere. Titration ladders, plateaus, protein targets, trend lines that slope down. Maintenance is quieter and much less discussed, and it is where a lot of people find themselves without a map.
The honest starting point is that this is not a finish line, and it is not a life sentence either. It is a change in what you are watching, and a set of decisions that belong in a clinic rather than on a website.
What the studies report about stopping
The research on stopping GLP-1 medications is reasonably consistent, and reporting it plainly is more respectful than softening it.
A systematic review and meta-regression reported that roughly 60 percent of the weight lost during treatment was regained by about one year after stopping, with the trajectory estimated to level off somewhere near 75 percent of the lost weight beyond about 52 weeks. Individual trials point the same direction. In STEP-10, more than 40 percent of the weight lost was regained within 28 weeks of stopping semaglutide. In SURMOUNT-4, more than 50 percent of the weight lost rebounded over 52 weeks after tirzepatide was withdrawn.
Every one of those numbers is a group average from a study population under study conditions. None of them is a forecast for a particular person, and none of them describes an inevitability. They describe what happened, on average, to groups of people who were followed after treatment ended.
The framing used in the literature around these findings is worth knowing too. Obesity is described as a chronic, relapsing condition, and long-term treatment of some kind is generally considered necessary to maintain weight loss. That framing is also where the genuine uncertainty sits: whether every person needs indefinite medication is not settled, and anyone claiming otherwise in either direction is going beyond what the evidence supports.
Why the averages hide the person
Group averages are useful for planning and terrible for prediction, and this is a case where the gap really matters.
Individual variability here is large and real. Some people regain quickly. Some regain slowly. Some hold steady for a long time. Some restart at a lower dose. Some find that circumstances, appetite and habits land somewhere they did not expect at all. A figure like 60 percent at one year is the middle of a wide spread, and almost nobody lives at the middle of a wide spread.
That is not a reason to dismiss the numbers. It is a reason to hold them the way a clinician does: as context that shapes the conversation, not as a script for what your next year will look like.
Whose decision this is
This is the part where we are going to be firm about our own limits, because the topic attracts confident advice from people who are not entitled to give it.
Whether to continue a GLP-1 after reaching a goal weight, whether to reduce a dose, whether to change the interval, and whether to stop are all prescriber decisions, made with you, based on your history, your other conditions, your response so far and your preferences. We will not tell you to stop. We will not tell you to continue. We will not sketch a tapering approach, not even a general one, because a general approach applied to a specific person without examination is exactly the failure mode that makes internet health writing dangerous.
What we will say is that this is worth raising early rather than at the moment it becomes urgent. Ask the question at a routine visit, before insurance, supply or life forces the timing. Our guide to preparing for an appointment covers how to bring data into a conversation like this so the fifteen minutes are spent on the decision rather than on reconstructing what happened.
GLP 1 Tracker AppWeight trends, protein, doses and side effects in one place, and Premium keeps the whole history rather than the last month. Free to start, no account.
Get the app
What maintenance tracking actually looks like
The question you are asking your data has changed. During loss it was "is this working, and how fast." In maintenance it is "is this holding." That is a different question, and it needs less intensity but more patience.
The trend still matters more than the reading. A single morning weight in maintenance is, if anything, even noisier than it was during active loss, because there is no underlying slope to drown out the day-to-day fluctuation from salt, sleep, hydration and hormones. Our article on daily versus weekly weigh-ins lays out both approaches, and either works here. What does not work is reading individual numbers as verdicts, which becomes tempting precisely when there is no longer a downward trend to reassure you.
A useful habit is to decide, in advance and while calm, what would actually count as a signal worth acting on. Not a number that ruins a Tuesday, but a sustained direction over several weeks. Deciding that ahead of time is much easier than deciding it while looking at a scale you do not like.
Monthly measurements still earn their place too. Waist, hips, chest, thigh and arm move on their own schedule, and body composition can shift while the scale sits still, which is exactly the scenario maintenance produces most often. Our guide to measurements beyond the scale covers the practical version, and the non-scale progress piece is arguably more relevant in maintenance than it was during loss.
The numbers that do not retire
A few things stay exactly as important as they were, and it is easy to let them slide once the headline number stops moving.
- Protein. Commonly cited guidance for people on GLP-1s is roughly 1.0 to 1.5 grams per kilogram of body weight daily, and the reason is lean mass, which does not become less valuable once you hit a target. See our guide to protein goals.
- Resistance training. Strength work is the other half of protecting lean mass, and two sessions a week is the version most people can sustain. Our strength training article covers what that actually involves.
- Hydration and fiber. If appetite is still suppressed, both are still at risk, and both still affect how you feel day to day.
- The dose log. If the medication continues in any form, the log keeps doing what it always did: exact dates, no reconstruction from memory.
And if a dose does change for any reason, side effect logging becomes worth doing properly again. The reasons are the same as during titration: patterns cluster around changes, and a severity note written on the day beats a guess made three weeks later in an exam room. Our guide to tracking side effects applies unchanged.
Not a graduation, and not a sentence
Two framings tend to cause trouble here, and they fail in opposite directions.
The first treats the goal weight as a graduation: the work is done, the tracking can stop, the habits were scaffolding for a project that has now shipped. The research on regain is the honest answer to that one, and it is why maintenance deserves its own attention rather than benign neglect.
The second treats the research as a verdict already delivered, which is just as inaccurate and considerably more demoralizing. The figures above describe averages across groups, the spread around them is wide, and the trajectory of any individual is not written in a meta-regression. People do maintain. The uncertainty in this field runs in both directions.
What is left, between those two, is unglamorous and workable. Keep watching the trend rather than the reading. Keep the protein and the strength work. Notice a sustained direction early rather than late. And have the conversation about what comes next with the person qualified to have it, at a routine visit, before anything forces the question.
Frequently asked questions
Will I regain the weight if I stop taking my GLP-1?
Regain after stopping is common and well documented in published research. A systematic review and meta-regression reported that roughly 60 percent of the weight lost during treatment was regained by about one year after stopping, with the trajectory estimated to level off near 75 percent of the lost weight beyond about 52 weeks. Those are group averages from studies, not a forecast for any one person, and individual results vary a great deal.
What happened in the studies that stopped semaglutide and tirzepatide?
In STEP-10, more than 40 percent of the weight lost was regained within 28 weeks of stopping semaglutide. In SURMOUNT-4, more than 50 percent of the weight lost rebounded over 52 weeks after tirzepatide was withdrawn. Both are findings about study populations under study conditions. They describe averages across groups and do not predict what will happen to a particular person.
Do I have to stay on a GLP-1 forever after reaching my goal?
That is a question for your prescriber, and it is genuinely unsettled. Obesity is described in the literature as a chronic, relapsing condition, and long-term treatment of some kind is generally considered necessary to maintain weight loss. Real uncertainty remains about whether every person needs indefinite medication. Whether to continue, reduce, or stop is a clinical decision made with you, not something a website can answer.
What should I track once I reach my goal weight?
Roughly what you tracked before, at a lower intensity, with the emphasis moved from progress to stability. A weight trend over weeks still beats any single reading. Monthly measurements still catch changes the scale misses. Protein and strength work still matter for lean mass. And if a dose changes for any reason, side effect logging becomes useful again for the same reasons it was useful during titration.
How often should I weigh myself in maintenance?
Either daily or weekly works, and the better choice is the one you will actually keep up without it souring your week. Daily weighing produces noisier readings but a smoother trend line. Weekly weighing produces quieter data with a bumpier trend. In maintenance the question you are asking has changed from how fast is this falling to is this holding, and the trend answers that either way.